Core Viewpoint - The stock of Kedi-B (02487) has risen over 10%, currently up 10.11% at HKD 7.19, with a trading volume of HKD 5.7763 million, following the announcement of the commercialization of its innovative products [1] Group 1: Product Launches - Kedi Group has announced the first batch of its original imported 4% Minocycline Hydrochloride Foam (Anzqing) has been shipped from its Wuxi factory to various locations across the country, marking it as the world's first and only topical 4% Minocycline Hydrochloride Foam for treating moderate to severe inflammatory lesions of acne in patients aged 9 and above [1] - On October 17, Kedi Group announced the first batch of its original imported Finasteride Spray (brand name: Finjuve) has been shipped from Shanghai Pharmaceutical International Supply Chain Co., Ltd. to various locations nationwide, with sales officially starting in China on October 20 [1] Group 2: Market Position and Growth Potential - According to Caitong Securities, the company is emerging as a new star in the field of dermatological treatments, with its two core products possessing strong differentiation advantages, which are expected to inject growth momentum into the company's performance as commercialization progresses [1] - According to Kaiyuan Securities, the company has established a diversified product portfolio covering hair diseases, skin care, and medical aesthetics, and is optimistic about the growth potential under the accelerated commercialization process of its dense pipeline [1]
科笛-B涨超10% 外用米诺环素泡沫剂、非那雄胺喷雾剂国内开启销售